Liposomal Amphotericin B in Invasive Aspergillosis With Hepatic Dysfunction

Inclusion criteria

• ✓. Willing to participate in the study and able to provide written informed consent;
• ✓. Hospitalized patients admitted to the intensive care unit (ICU);
• ✓. Age ≥ 18 years, with no restriction on sex;
• ✓. Proven or probable invasive aspergillosis (IA), defined as follows:
• ✓. Histopathological or cytopathological evidence of invasive Aspergillus spp. hyphae in tissue specimens obtained from a sterile site or the lung (e.g., biopsy or needle aspiration), with confirmation by culture or polymerase chain reaction (PCR);
• ✓. Isolation of Aspergillus spp. by culture from a specimen obtained from a sterile site (e.g., biopsy or needle aspiration), with the lesion consistent with an infectious process.
• ✓. At least one host factor (e.g., COVID-19, influenza, solid malignancy, HIV infection with CD4 \<200 cells/µL, decompensated liver cirrhosis, or moderate to severe chronic obstructive pulmonary disease \[COPD\]);
• ✓. At least one compatible clinical feature (e.g., fever ≥38.3 °C lasting ≥3 days, pleuritic chest pain, dyspnea, hemoptysis, or worsening respiratory failure despite appropriate antibacterial therapy);

Exclusion criteria